SGLT2 inhibitors: an emerging option for cardiologists?

Earlier this year, Boehringer Ingelheim and Lilly announced an expansion to the clinical trial programme for Jardiance (empagliflozin) in chronic heart failure. The SGLT2 inhibitor drug, which is used to treat patients with type 2 diabetes, was previousl https://pharmaphorum.com/views-and-analysis/sglt2-inhibitors-cardiologists-option/